Search Within

Ghassan Abou-Alfa

Formats
  1. Meeting Abstract (262)
  2. Journal Article (245)
  3. Review (26)
  4. Book Section (16)
  5. Editorial (8)
  6. Book Whole (4)
  7. Correspondence (4)
  8. Guidelines (4)
  9. Miscellaneous (3)
  10. Research Letter (1)
Groups
  1. Department of Medicine (573)
  2. Gastrointestinal Oncology Service (573)
  3. Solid Tumor Oncology Division (573)
  4. Center for Pancreatic Cancer Research (215)
  5. Epidemiology and Biostatistics (122)
  6. Surgery (103)

More Groups

People
  1. Eileen O'Reilly (156)
  2. James Harding (130)
  3. William Jarnagin (66)
  4. Marinela Capanu (65)
  5. Leonard Saltz (55)
  6. Imane El Dika (54)

More People

Years
  1. 2025 (18)
  2. 2024 (52)
  3. 2023 (48)
  4. 2022 (53)
  5. 2021 (46)
  6. 2020 (46)

More Years

Publications
  1. Journal of Clinical Oncology (166)
  2. Annals of Oncology (53)
  3. Gastrointestinal Cancer Research (21)
  4. Oncology Research and Treatment (18)
  5. Annals of Surgical Oncology (15)
  6. Cancer (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (182)
  2. Oxford University Press (65)
  3. Springer (36)
  4. Wiley Blackwell (30)
  5. Elsevier Inc. (25)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (573)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Medical therapy options for advanced disease in hepatocellular carcinoma
    Book Section

    El Dika, I.; Abou-Alfa, G. K.
    In Cardona, K.; Maithel, S. K. (Eds.) Primary and Metastatic Liver Tumors: Treatment Strategy and Evolving Therapies (2018)

    Fulltext@MSK | Save
  • Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
    Meeting Abstract

    Javle, M.; Kelley, R. K.; Roychowdhury, S.; Weiss, K. H.; Abou-Alfa, G. K.; Macarulla, T.; Sadeghi, S.; Waldschmidt, D.; Zhu, A. X.; Goyal, L.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of disease burden in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Blanc, J. F.; Meyer, T.; Cheng, A. L.; El-Khoueiry, A. B.; Cicin, I.; Chen, Y.; Bolondi, L.; Dadduzio, V.; Baron, A.; Lin, Z. Z.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Interim results of fight-202, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with previously treated advanced/metastatic or surgically unresectable cholangiocarcinoma (CCA) with/without fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations
    Meeting Abstract

    Hollebecque, A.; Borad, M.; Sahai, V.; Catenacci, D. V. T.; Murphy, A.; Vaccaro, G.; Paulson, A.; Oh, D. Y.; Féliz, L.; Lihou, C.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes by prior transarterial chemoembolization (TACE) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Yau, T.; Cheng, A. L.; Meyer, T.; Ryoo, B. Y.; Park, J. W.; Klümpen, H. J.; Lim, H. Y.; Kim, S.; Knox, J.; Patel, M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Outcomes by baseline alpha-fetoprotein (AFP) levels in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Kelley, R. K.; El-Khoueiry, A. B.; Meyer, T.; Rimassa, L.; Merle, P.; Chan, S. L.; Tran, A.; Parnis, F.; Tam, V. C.; Cattan, S.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)
    Meeting Abstract

    Yau, T.; Merle, P.; Rimassa, L.; Ryoo, B. Y.; Cicin, I.; Harris, W. P.; Banu, E.; Sarker, D.; Tan, B.; van Vlierberghe, H.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • HALO 110-101: Phase Ib study of PEGPH20 in combination with cisplatin plus gemcitabine (PEGCISGEM) or atezolizumab (ATEZO) plus CIS plus GEM (PEGCISGEMATEZO) in patients with locally advanced/metastatic cholangiocarcinoma and gallbladder cancer
    Meeting Abstract

    Oh, D. Y.; Park, J. O.; Charoentum, C.; Stein, S.; Noel, M.; Chung, V.; Wu, W.; Alton, R.; Muhsin, M.; Javle, M.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • HALO 110-101: A phase Ib, randomized, open-label study of PEGPH20 (pegvorhyaluronidase alfa) in combination with cisplatin (CIS) + gemcitabine (GEM) (PEGCISGEM) or atezolizumab and CIS + GEM (PEGCISGEMATEZO) in hyaluronan-high subjects with locally advanced or metastatic cholangiocarcinoma and gallbladder cancer
    Meeting Abstract

    Borad, M. J.; Shroff, R. T.; Abou-Alfa, G. K.; Hecht, J. R.; Bullock, A. J.; Ritch, P. S.; Chondros, D.; Muhsin, M.; Oh, D. Y.
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • ClarIDHy: A phase 3 multicenter randomized double-blind study of AG-120 versus placebo in patients with non-resectable or metastatic cholangiocarcinoma with an IDH1 mutation
    Meeting Abstract

    Abou-Alfa, G. K.; Valle, J. W.; Kelley, R. K.; Goyal, L.; Shroff, R. T.; Javle, M. M.; Borad, M. J.; Cleary, J. M.; El-Khoueiry, A. B.; Bendell, J. C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save